This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NamePlozalizumab
Accession NumberDB12520  (DB05486)
TypeBiotech
GroupsInvestigational
Description

Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs MLN-1202 / MLN1202
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNII4XG66BMN0D
CAS number1610761-46-0
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. Plozalizumab targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes.

TargetKindPharmacological actionActionsOrganismUniProt ID
C-C chemokine receptor type 2ProteinunknownNot AvailableHumanP41597 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingOtherMelanoma1
1WithdrawnTreatmentHealthy Japanese and Caucasian Male Adults1
2CompletedTreatmentAtherosclerosis1
2CompletedTreatmentDisseminated Sclerosis1
2WithdrawnTreatmentAtherosclerotic Cardiovascular Diseases1
2WithdrawnTreatmentDiabetic Nephropathies1
Properties
StateNot Available
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Receptor for the CCL2, CCL7 and CCL13 chemokines. Transduces a signal by increasing intracellular calcium ion levels. Alternative coreceptor with CD4 for HIV-1 infection.
Gene Name:
CCR2
Uniprot ID:
P41597
Molecular Weight:
41914.265 Da
Drug created on October 20, 2016 16:41 / Updated on June 07, 2017 15:26